Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus arteriosus who are nonresponsive to medical management. The Amplatzer Piccolo ...

The device was delivered either through an ... outcomes included absence of continuous murmur and rate of patent ductus arteriosus closure at 6 months. Both sets of outcomes were compared against ...

Pantai Hospital Kuala Lumpur (PHKL) marked a significant milestone in cardiovascular care with the successful transcatheter ...

Indomethacin is the conventional treatment for patent ... ductus arteriosus (Table 3). In centers that preferentially used high-frequency oscillatory ventilation, overall rates of ductal closure ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA ... "Whether early use of newer pharmacologic ...

As a result, 70 percent of preterm infants delivered before 28 weeks of gestation require either medical or surgical closure of a patent ductus arteriosus. The clinical consequences of a patent ...

The Bloom Micro Occluder System is a minimally invasive device designed to treat patent ductus arteriosus (PDA ... “Options for transcatheter device closure of PDA are limited,” said Thomas ...

Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD ...